{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:04:39Z","timestamp":1773029079357,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Fc\u2010engineered antibodies (mAbs) enhancing FcRn binding have rapidly expanded in drug discovery and development. Although an approach exists for predicting the pharmacokinetics of Fc\u2010engineered mAbs after intravenous injections in humans, no methodology has been established for predicting pharmacokinetics after subcutaneous injections. This study aimed to establish a methodology for predicting the pharmacokinetics of Fc\u2010engineered mAbs after subcutaneous injections in humans. First, bioavailability (F) and absorption rate constant (k\n                    <jats:sub>a<\/jats:sub>\n                    ) values following subcutaneous injections in humans were collected and analyzed. Then, AUC after subcutaneous injections in humans was predicted using the geometric mean of reported F and allometrically scaled clearance (CL) from cynomolgus monkeys. Next, plasma concentration\u2010time profiles after subcutaneous injections were predicted using the geometric mean of reported F and k\n                    <jats:sub>a<\/jats:sub>\n                    values and allometrically scaled two\u2010compartment model parameters from cynomolgus monkeys. The geometric mean of reported F for Fc\u2010engineered mAbs in humans was 0.601, lower than that of normal mAbs. The geometric mean of ka was 0.284\/day, comparable to normal mAbs. The prediction accuracy of AUC using the geometric mean of F and scaled CL from cynomolgus monkeys was 95.2% within 2\u2010fold of observed values. Furthermore, C\n                    <jats:sub>max<\/jats:sub>\n                    and T\n                    <jats:sub>max<\/jats:sub>\n                    after subcutaneous injections showed 94.1% and 70.6% prediction accuracy within 2\u2010fold of observed values, respectively. Overall, 88.4% and 95.3% of whole plasma concentration\u2010time profiles were predicted within 2\u2010fold and 3\u2010fold of observed values, respectively, demonstrating the high prediction accuracy. This methodology, combining fixed absorption parameters with scaled two\u2010compartment model parameters, can significantly support Fc\u2010engineered mAbs development.\n                  <\/jats:p>","DOI":"10.1111\/cts.70482","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:43:49Z","timestamp":1769071429000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative Prediction of Human Pharmacokinetics for Fc\u2010Engineered Therapeutic Monoclonal Antibodies With Increased\n                    <scp>FcRn<\/scp>\n                    Binding Mutations After Subcutaneous Injection"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9142-5607","authenticated-orcid":false,"given":"Kenta","family":"Haraya","sequence":"first","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd  Yokohama Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Kuramochi","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co., Ltd  Yokohama Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00294-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2018.10.003"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2022.102809"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01285-13"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13612"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002493"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2017.05.002"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00566-2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2011.06.031"},{"key":"e_1_2_9_12_1","unstructured":"WIPO \u201cWO2015157238: Binding Molecules Specific for IL\u201021 and Uses Thereof \u201d(2015) https:\/\/patentscope.wipo.int\/search\/en\/WO2015157238."},{"key":"e_1_2_9_13_1","unstructured":"WIPO \u201cWO2018215964: Biopharmaceutical Compositions and Related Methods \u201d(2018) https:\/\/patentscope.wipo.int\/search\/en\/WO2018215964."},{"key":"e_1_2_9_14_1","unstructured":"WIPO \u201cWO2018071676: Anti\u2010C1S Antibodies and Methods of Use Thereof \u201d(2018) https:\/\/patentscope.wipo.int\/search\/en\/WO2018071676."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005862020"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12715"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15002"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac041"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13481"},{"issue":"8","key":"e_1_2_9_20_1","first-page":"4043","article-title":"Preclinical Pharmacokinetics of VRDN\u2010003, A Next\u2010Generation Half\u2010Life Extended Antibody to the IGF\u20101 Receptor for Thyroid Eye Disease","volume":"64","author":"Dickinson B.","year":"2023","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.2209"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.617265"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040519"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2230122"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16050594"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00003-6"},{"key":"e_1_2_9_27_1","volume-title":"A Phase I Dose\u2010Escalation Trial of Human Monoclonal Antibody N6LS in Healthy Adults","author":"Tw A.","year":"2020"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00793-9"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203067"},{"key":"e_1_2_9_30_1","volume-title":"A First\u2010in\u2010Human Study of the Trispecific HIV\u20101 Broadly Neutralizing Antibody, SAR441236 CROI","author":"Tsibris A.","year":"2024"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9367-0"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.2.19387"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2015.07.016"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.02.022"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2484443"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70482","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70482","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:13:57Z","timestamp":1773026037000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/cts.70482"],"URL":"https:\/\/doi.org\/10.1111\/cts.70482","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2025-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70482"}}